Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Phase 2 Active not recruiting 5 enrolled University of California, San Diego Oncternal Therapeutics, Inc · collab

NaSingle-groupOpen-labelTreatment

Single center, open-label, phase 2 study to determine the efficacy of cirmtuzumab consolidation in patients with measurable disease on venetoclax.

Evaluation	Drug	Modality	Dose	Route
Subject	Cirmtuzumab	Monoclonal antibody	600 mg	—
Background	Venetoclax	Small molecule	400 mg	Oral